RNF213

Across TCGA pan-cancer cohorts, RNF213 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RNF213 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RNF213 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RNF213 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, CCRCC, and PDAC are the cancer types where RNF213 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.755	0.296	<.001	25	view →
CCRCC	DFS	Median	IV	0.227	0.943	.001	22	view →
PDAC	OS	Tertile	All	0.770	0.890	.017	7	view →
GBM	DFS	Quartile	All	0.647	0.869	.018	3	view →
HNSC	DFS	Median	IV	1.000	0.924	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RNF213–LUAD (DFS)

Open the LUAD breakdown →